TY - JOUR
T1 - Effect of butylscopolamine on the quality MRI images of the prostate
AU - Wagner, M.
AU - Rief, M.
AU - Busch, J.
AU - Scheurig, C.
AU - Taupitz, M.
AU - Hamm, B.
AU - Franiel, T.
PY - 2010/6
Y1 - 2010/6
N2 - Aim: To evaluate the impact of butylscopolamine on the quality of magnetic resonance imaging (MRI) images of the prostate. Material and methods: Eighty-two MRI examinations of the prostate were retrospectively analysed. MRI was performed with a combined endorectal/body phased-array coil including proton density-weighted (PD) sequence, T1-weighted turbo spin-echo (TSE)-sequence, and T2-weighted TSE-sequences. Forty milligrams of butylscopolamine was administered intramuscularly in 31 patients (im-group) and intravenously in 30 patients (iv-group). Twenty-one patients did not receive premedication with butylscopolamine (ø-group). Overall image quality, delineation of the bowel wall, and visualization of the prostate, neurovascular bundle, and pelvic lymph nodes were evaluated qualitatively using a five-point scale (from 1 = excellent to 5 = non-diagnostic/structure not discernible). Motion artefacts within the endorectal coil were quantified by baseline adjusted signal intensities inside the endorectal coil area. Results: Delineation of the bowel wall using the PD-sequence was significantly improved after both intramuscular and intravenous butylscopolamine administration (ø-group: 3.6 ± 0.7; im-group: 2.9 ± 0.7; iv-group: 2.9 ± 0.7; p = 0.001). However, there were no significant differences in motion artefacts measured within the endorectal coil (ø-group: 1.18 ± 0.14; im-group: 1.15 ± 0.11; iv-group: 1.12 ± 0.06; p = 0.39). There were also no significant differences in qualitative assessment of visualization of the prostate, neurovascular bundle, pelvic lymph nodes, and of overall image quality between the study groups. Conclusion: : In conclusion, butylscopolamine had only a small effect on image quality and is not mandatory for MRI of the prostate.
AB - Aim: To evaluate the impact of butylscopolamine on the quality of magnetic resonance imaging (MRI) images of the prostate. Material and methods: Eighty-two MRI examinations of the prostate were retrospectively analysed. MRI was performed with a combined endorectal/body phased-array coil including proton density-weighted (PD) sequence, T1-weighted turbo spin-echo (TSE)-sequence, and T2-weighted TSE-sequences. Forty milligrams of butylscopolamine was administered intramuscularly in 31 patients (im-group) and intravenously in 30 patients (iv-group). Twenty-one patients did not receive premedication with butylscopolamine (ø-group). Overall image quality, delineation of the bowel wall, and visualization of the prostate, neurovascular bundle, and pelvic lymph nodes were evaluated qualitatively using a five-point scale (from 1 = excellent to 5 = non-diagnostic/structure not discernible). Motion artefacts within the endorectal coil were quantified by baseline adjusted signal intensities inside the endorectal coil area. Results: Delineation of the bowel wall using the PD-sequence was significantly improved after both intramuscular and intravenous butylscopolamine administration (ø-group: 3.6 ± 0.7; im-group: 2.9 ± 0.7; iv-group: 2.9 ± 0.7; p = 0.001). However, there were no significant differences in motion artefacts measured within the endorectal coil (ø-group: 1.18 ± 0.14; im-group: 1.15 ± 0.11; iv-group: 1.12 ± 0.06; p = 0.39). There were also no significant differences in qualitative assessment of visualization of the prostate, neurovascular bundle, pelvic lymph nodes, and of overall image quality between the study groups. Conclusion: : In conclusion, butylscopolamine had only a small effect on image quality and is not mandatory for MRI of the prostate.
UR - http://www.scopus.com/inward/record.url?scp=77951698335&partnerID=8YFLogxK
U2 - 10.1016/j.crad.2010.02.007
DO - 10.1016/j.crad.2010.02.007
M3 - Article
C2 - 20451013
AN - SCOPUS:77951698335
SN - 0009-9260
VL - 65
SP - 460
EP - 464
JO - Clinical Radiology
JF - Clinical Radiology
IS - 6
ER -